Nationwide Experience With Off-Label Use of Interleukin-1 Targeting Treatment in Familial Mediterranean Fever Patients.


Creative Commons License

AKAR S., Cetin P., KALYONCU U., KARADAĞ Ö., Sari I., Cinar M., ...More

Arthritis care & research, vol.70, no.7, pp.1090-1094, 2018 (Journal Indexed in SCI Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 70 Issue: 7
  • Publication Date: 2018
  • Doi Number: 10.1002/acr.23446
  • Title of Journal : Arthritis care & research
  • Page Numbers: pp.1090-1094

Abstract

ObjectiveApproximately 30-45% of patients with familial Mediterranean fever (FMF) have been reported to have attacks despite colchicine treatment. Currently, data on the treatment of colchicine-unresponsive or colchicine-intolerant FMF patients are limited; the most promising alternatives seem to be anti-interleukin-1 (anti-IL-1) agents. Here we report our experience with the off-label use of anti-IL-1 agents in a large group of FMF patients.